Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2005

01-08-2005

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer

Authors: Takahiko Sugiura, Yutaka Ariyoshi, Shunichi Negoro, Shinichiro Nakamura, Harumichi Ikegami, Minoru Takada, Takashi Yana, Masahiro Fukuoka

Published in: Investigational New Drugs | Issue 4/2005

Login to get access
Metadata
Title
Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer
Authors
Takahiko Sugiura
Yutaka Ariyoshi
Shunichi Negoro
Shinichiro Nakamura
Harumichi Ikegami
Minoru Takada
Takashi Yana
Masahiro Fukuoka
Publication date
01-08-2005
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2005
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-1441-3

Other articles of this Issue 4/2005

Investigational New Drugs 4/2005 Go to the issue

OriginalPaper

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors

OriginalPaper

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

Erratum

Pomegranate (Punica granatum) Pure Chemicals Show Possible Synergistic Inhibition of Human PC-3 Prostate Cancer Cell Invasion Across Matrigeltm

Erratum

Phase I Study of Tomudex and Doxorubicin in Patients with Locally Advanced, Inoperable or Metastatic Cancer (IND.98)

OriginalPaper

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid

OriginalPaper

Human metabolism of [14C]indisulam following i.v. infusion in cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits